Intercept Pharmaceuticals Inc.

20.80+0.6100+3.02%Vol 747.05K1Y Perf -74.60%
Apr 20th, 2021 16:00 DELAYED
BID19.91 ASK20.99
Open20.00 Previous Close20.19
Pre-Market- After-Market20.75
 - -  -0.05 -0.24%
Target Price
47.78 
Analyst Rating
Moderate Buy 1.56
Potential %
129.71 
Finscreener Ranking
★★★★     54.80
Insiders Trans % 3/6/12 mo.
100/50/-50 
Value Ranking
★★     46.99
Insiders Value % 3/6/12 mo.
100/98/-94 
Growth Ranking
★★★+     55.27
Insiders Shares Cnt. % 3/6/12 mo.
100/99/-84 
Income Ranking
 —    -
Market Cap689.77M 
Earnings Rating
Buy
Price Range Ratio 52W %
3.40 
Earnings Date
10th May 2021

Today's Price Range

19.8021.00

52W Range

18.1595.98

5 Year PE Ratio Range

-9.40-8.10

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-2.85%
1 Month
-8.37%
3 Months
-25.93%
6 Months
-29.44%
1 Year
-74.60%
3 Years
-69.74%
5 Years
-86.21%
10 Years
-

TickerPriceChg.Chg.%
ICPT20.800.61003.02
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Financial StrengthValueIndustryS&P 500US Markets
2.90
3.00
0.91
10.45
-4.70
Leverage Ratio -5.00
ProfitabilityValueIndustryS&P 500US Markets
98.30
-90.90
-89.80
-465.30
-74.01
RevenueValueIndustryS&P 500US Markets
240.04M
7.24
30.02
157.43
Earnings HistoryEstimateReportedSurprise %
Q04 2020-1.55-1.58-1.94
Q03 2020-1.96-2.01-2.55
Q02 2020-2.94-1.9234.69
Q01 2020-2.94-2.862.72
Q04 2019-2.56-2.99-16.80
Q03 2019-2.35-2.59-10.21
Q02 2019-2.51-2.289.16
Q01 2019-2.57-3.03-17.90
Earnings Per EndEstimateRevision %Trend
3/2021 QR-1.535.56Positive
6/2021 QR-1.414.73Positive
12/2021 FY-5.5913.87Positive
12/2022 FY-4.94-6.01Negative
Next Report Date10th May 2021
Estimated EPS Next Report-1.53
Estimates Count10
EPS Growth Next 5 Years %-
Volume Overview
Volume747.05K
Shares Outstanding33.16M
Trades Count8.60K
Dollar Volume61.11M
Avg. Volume1.18M
Avg. Weekly Volume2.12M
Avg. Monthly Volume1.31M
Avg. Quarterly Volume1.15M

Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) stock closed at 20.8 per share at the end of the most recent trading day (a 3.02% change compared to the prior day closing price) with a volume of 771.71K shares and market capitalization of 689.77M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 498 people. Intercept Pharmaceuticals Inc. CEO is Jerome B. Durso.

The one-year performance of Intercept Pharmaceuticals Inc. stock is -74.6%, while year-to-date (YTD) performance is -15.79%. ICPT stock has a five-year performance of -86.21%. Its 52-week range is between 18.15 and 95.98, which gives ICPT stock a 52-week price range ratio of 3.40%

Intercept Pharmaceuticals Inc. currently has a PE ratio of -2.40, a price-to-book (PB) ratio of 52.34, a price-to-sale (PS) ratio of 2.79, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -39.20%, a ROC of -49.87% and a ROE of 496.52%. The company’s profit margin is -74.01%, its EBITDA margin is -89.80%, and its revenue ttm is $240.04 Million , which makes it $7.24 revenue per share.

Of the last four earnings reports from Intercept Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.53 for the next earnings report. Intercept Pharmaceuticals Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for Intercept Pharmaceuticals Inc. is Moderate Buy (1.56), with a target price of $47.78, which is +129.71% compared to the current price. The earnings rating for Intercept Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Intercept Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Intercept Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 27.91, ATR14 : 1.92, CCI20 : -149.14, Chaikin Money Flow : -0.15, MACD : -2.68, Money Flow Index : 51.23, ROC : -12.52, RSI : 30.34, STOCH (14,3) : 11.58, STOCH RSI : 0.00, UO : 40.08, Williams %R : -88.42), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Intercept Pharmaceuticals Inc. in the last 12-months were: Christian Weyer (Sold 181 shares of value $15 557 ), Jason Campagna (Sold 1 192 shares of value $56 543 ), Paolo Fundaro (Sold 2 691 156 shares of value $172 020 460 ), Sandip S. Kapadia (Sold 1 763 shares of value $57 791 ), Srinivas Akkaraju (Buy at a value of $5 016 252)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (68.75 %)
11 (73.33 %)
12 (80.00 %)
Moderate Buy
1 (6.25 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (25.00 %)
4 (26.67 %)
3 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.56
Strong Buy
1.53
Strong Buy
1.40

Intercept Pharmaceuticals Inc.

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor.

CEO: Jerome B. Durso

Telephone: +1 646 747-1000

Address: 10 Hudson Yards, New York 10001, NY, US

Number of employees: 498

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

54%46%

Bearish Bullish

59%41%

News

Stocktwits